Group ACYW₁₃₅ Meningococcal Conjugate Vaccine

[Dosage Form] 

The package is collective packing containing two vials, one vial of white loose substance (freeze-dried group A, group C), the other vial of clear liquid (group Y, group  W₁₃₅).

[Indication] 

It is indicated for prevention against epidemic cerebrospinal meningitis caused by group A, group C, group Y and group W₁₃₅ meningococcus.

[Specification]

Each 0.5 ml per human dose of reconstituted vaccine contains no less than 10μg of each meningococcal capsular polysaccharide of group A, group C; no less than 5μg of each meningococcal capsular polysaccharide of group Y, group W₁₃₅.

[Route of Administration]

Intramuscular injection of 0.5ml/dose. The vaccination site of the recipients under 12 months old is the anterolateral thigh, while deltoid insertion area of the lateral upper arm for recipients at or above 12 months old.

[Shelf life]
18 months